personalized therapy
Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?
... Reactive oxygen species (ROS) generated during in- flammation induces DNA damage that is processed through DNA repair in cells. Whereas suboptimal DNA repair may predispose to cancer, evolving data also sug- gest that ...
7
Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
... anti-TNF-α therapy is a mainstay of treatment for many; however, systemic immunosuppression is not universally effective and is associated with potential side ...
10
Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy
... interferon-alpha therapy is usually modest be- cause it is not effective for all patients, and it is difficult to determine which patients will respond well to interferon-alpha ...to therapy with ...alpha ...
8
DNA repair in cancer: emerging targets for personalized therapy
... Abstract: Genomic deoxyribonucleic acid (DNA) is under constant threat from endogenous and exogenous DNA damaging agents. Mammalian cells have evolved highly conserved DNA repair machinery to process DNA damage and ...
16
Personalized therapy for lung cancer: striking a moving target
... therapy, and demonstrated robust superiority over chemotherapy. Interestingly, none of the patients treated with osimertinib as first-line therapy developed T790M-mediated acquired resistance. Escape ...
15
Dawn for Personalized Therapy in Non-small Cell Lung Cancer
... first-line therapy in EGFR mutated NSCLC, and confirmed as the primary end point that progression-free survival (PFS) in the gefitinib group was significantly longer than that in the carboplatin plus paclitaxel ...
11
Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
... mono- therapy was promising (44% response in FLT3-ITD pa- tients with relapsed/refractory AML treated with AC220, quizartinib [180, 181]), this did not result in prolonged disease-free survival ...
17
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
... “drug therapy”—without restrictions to date. Furthermore, references cited in the retrieved articles were screened for additional articles. Moreover, proceedings from the American Society of Clinical Oncology ...
19
An Evolutionary Approach for Personalized Therapy in Multiple Myeloma
... The therapeutic approach described here is based on the assumption of the pre-existence of therapy-resistant cells, and seeks to prevent the emergent growth of this refractory population for as long as possible. ...
11
Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach
... In all subcategories (Figure 2), treatment starts with lifestyle intervention, ie, diabetes education, physical activity, and medical nutritional therapy. We support the recommenda- tion to intervene on lifestyle ...
8
DNA repair in cancer: emerging targets for personalized therapy
... Abstract: Genomic deoxyribonucleic acid (DNA) is under constant threat from endogenous and exogenous DNA damaging agents. Mammalian cells have evolved highly conserved DNA repair machinery to process DNA damage and ...
16
Cancer Stem Cells in the Personalized Therapy of Colorectal Cancer
... such therapy and retain their tumor-conditioned phenotype, thus potentially contributing to disease ...enzyme/prodrug therapy: this therapy can be selective against the neoplastic cells and the ...
13
Precision medicine and personalized breast cancer: combination pertuzumab therapy
... Pertuzumab is the first neoadjuvant drug to receive accelerated approved by the FDA based on pCR as the pri- mary end point. The full approval is contingent on the final results of APHINITY, the confirmatory study ...
11
The quest for an effective and safe personalized cell therapy using epigenetic tools
... for personalized medicine have been approved by FDA, various challenges still exist, given the observation that each patient is unique and, similarly, displays a unique epigenomic ...
9
Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy
... agents containing both therapeutic and imaging functions [5, 6]. It is generally considered that using nanoscale carriers is critical to achieving long blood circulation (by escaping both renal clearance and hepatic ...
16
<p>A personalized approach to acute myeloid leukemia therapy: current options</p>
... The CD33 antigen is a transmembrane receptor and myeloid- differentiation marker that is expressed in most AMLs. It's extracellular immunoglobulin-like V domain can be exploited using antibody – drug conjugate ...
13
Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE
... Infusion of amino acids (Vamin 18 g N/L electrolyte-free, Fresenius Kabi) was started at least half an hour prior to administration of the radiopharmaceutical and continued for sev- eral hours (4–6 h). As standard ...
15
Personalized versus non personalized computerized decision support system to increase therapeutic quality control of oral anticoagulant therapy: an alternating time series analysis
... Methods: The study is an alternating time series experiment with three 6 months periods, each one including every 2 months according to a Latin square scheme: a control period without any reminder, a period with the ...
8
Physiology and technology for the ICU in vivo
... drug therapy, there is a need for more precise homing of therapeutic drugs and a need to know whether the drug has achieved its delivery and accomplished its therapeutic action, an ap- proach referred to as ...
6
Massive open online courses : an adaptive learning framework
... Adaptive learning is a system of learning that customises the structure of learning contents to the desire of the individual learners. Nowadays they system is said to be modelling the learners. This concept has high ...
11